AUIC — The Universal Parameter within the Constraint of a Reasonable Dosing Interval

Schentag JJ Paladino JA Birmingham MC Zimmer G Carr JR Hanson SC . Use of benchmarking techniques to justify the evolution of antibiotic management programs in healthcare systems. J Pharm Technol 1995; 11: 203–10.

Schentag JJ Carr JR Adelman MH Birmingham MC Zimmer GS Paladino JA . Formulary management vs disease management. Infect Dis Clin Pract 1996; 5 (suppl 1): 1–6.

Schentag JJ . Understanding and managing microbial resistance in institutional settings. Am J Health-Syst Pharm 1995; 52 (suppl 2): S9–14.

Dalla Costa T Derendorf H . AUIC — a general target for the optimization of dosing regimens of antibiotics? Ann Pharmacother 1996; 30: 1024–8.

Craig WA Redington J Ebert SC . Pharmacodynamics of amikacin in vitro and in mouse thigh infections. J Antimicrob Chemother 1991; 27 (suppl C): 29–40.

Vogelman B Gudmundsson S Leggett J Tumidge J Craig WA . Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158: 831–47.

Leggett J Fantin B Ebert S Totusak K Craig WA . Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh infection models. J Infect Dis 1989; 159: 281–92.

Dudley MN . Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones. Am J Med 1991; 91 (suppl 6A): 45S–50S.

Drusano GL . Human pharmacodynamics of beta lactams, aminoglycosides, and their combination. Scand J Infect Dis 1991; 74 (suppl): 235–48.

Moore RD Lietman PS Smith CR . Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to MIC. J Infect Dis 1987; 155: 93–9.

Nix DE Tyrrell R Muller M . Pharmacodynamics of metronidazole determined by a time kill assay for Trichomonas vaginalis. Antimicrob Agents Chemother 1995; 39: 1848–52.

Schentag JJ Nix DE Adelman MH . Mathematical examination of dual individualization principles (I): relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP Ann Pharmacother 1991; 25: 1050–7.

Luzier A Goss TF Cumbo TJ Schentag JJ . Mathematical examination of dual individualization principles (III): development of a scoring system for pneumonia staging and quantitation of response to antibiotics: results in cefmenoxime-treated patients. Ann Pharmacother 1992; 26: 1358–65.

Goss TF Forrest A Nix DE Ballow CH Birmingham MC Cumbo TJ Mathematical examination of dual individualization principles (II): the rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime. Ann Pharmacother 1994; 28: 863–8.

Forrest A Nix DE Ballow CH Goss TF Birmingham MC Schentag JJ . The pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073–81.

Forrest A Amantea M Collins D Chodosh S Schentag JJ . Pharmacodynamics of oral OPC17116 in patients with acute bacterial exacerbations of chronic bronchitis (abstract). 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, October 17–20, 1993: 134.

Ballow CH Amsden GW Forrest A Highet VS Schentag JJ . Control of antimicrobial activity exposure in the treatment of gram negative infections (abstract). 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, October 17–20, 1993: 134.

Highet VS Ballow CH Forrest A . Population derived AUIC is predictive of efficacy (abstract). New Orleans: American Society for Clinical Pharmacology and Therapeutics, March 30-April 1, 1994.

Hyatt JM McKinnon PS Zimmer GZ Schentag JJ . The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 1995; 28: 143–60.

Hyatt JM Nix DE Schentag JJ . Pharmacokinetic and pharmacodynamic activity of ciprofloxacin against strains of S. pneumoniae, S. aureus, and P. aeruginosa for which MICs are similar. Antimicrob Agents Chemother 1994; 38: 2730–7.

McKinnon PS Paladino JA Schentag JJ . Evaluation of AUC/MIC and time above the MIC as predictors of outcome for advanced genèration cephalosporins in serious bacterial infections (abstract). 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17–20, 1995: 11.

Nix DE Schentag JJ . The role of pharmacokinetics and pharmacodynamics in the design of dosage schedules for 12 hr cefotaxime alone and in combination with other antibiotics. Diagn Microbiol Infect Dis 1995; 22: 71–6.

Hyatt JM Schentag JJ . Risk factors for selection of Pseudomonas aeruginosa resistance to ciprofloxacin in patients with previously susceptible strains (abstract). 6th Annual Meeting of SHEA, the Society for Healthcare Epidemiology of America, Washington, DC, April 21–23, 1996.

Hyatt JM Gutfeld MB Schentag JJ . Epidemiologic assessment of antimicrobial usage patterns and development of bacterial resistance (abstract). 6th Annual Meeting of SHEA, the Society for Healthcare Epidemiology of America, San Diego, CA, April 2–4, 1995.

McCormack JP Schentag JJ . Potential impact of quantitative susceptibility tests on the design of aminoglycoside dosing regimens. Drug Intell Clin Pharm 1987; 21: 187–92.

Paladino JA Fell RE . Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia. Ann Pharmacother 1994; 28: 384–9.

Schentag JJ Ballow CH Fritz AL Paladino JA Williams JD Cumbo TJ Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratory. Diagn Microbiol Infect Dis 1993; 16: 255–64.

Paladino JA Zimmer GS Schentag JJ . The economic potential of dual individualization methodologies. PharmacoEconomics 1996 (in press).

Neu HC . The crisis in antibiotic resistance. Science 1992; 257: 1064–72.